Velakast (Sofosbuvir + Velpatasvir) Tablets
Velakast (Sofosbuvir 400 mg + Velpatasvir 100 mg) is a fixed-dose combination generic of Epclusa, manufactured by Aprazer.
Official License: Produced under a license from Gilead Sciences, ensuring it meets the same quality standards as the original US brand. It is a "Pan-Genotypic" Direct-Acting Antiviral (DAA), meaning one pill cures all major strains of Hepatitis C.
Mechanism of Action:
By combining two potent inhibitors (NS5B + NS5A) in a single tablet, Velakast stops the virus from replicating and assembling new particles. It offers a simple, one-pill-a-day regimen.
✅ Efficacy: Cure rates exceeding 98-99% across all genotypes after a 12-week course.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 09.03.2026
What Customers Say
No reviews yet
Your review can be the first!